Background: Coronary artery disease (CAD) patients with a history of hypertension and underlying comorbidities are at high risk of developing major adverse cardiac events (MACE) and increase the mortality of the patients.Objective: This study aims to determine the association of hypertension and MACE in CAD patients admitted to ICCU.Method: This research is an analytic study with a cross-sectional approach. The data used is secondary data from the records of patients who were admitted to ICCU at Sanglah Hospital on 1 January 2021-31 December 2021 with total sampling technique.Result: There were 376 patients included in this study. The majority of patients were male (n=291,77.4%) with the median overall patient age of 58 years old. Most of MACE found in the patients were revascularization (n=113;30.1%). The prevalence of hypertension was 19.1%. There were signifi cant differences in length of in hemoglobin (p=0.006), lymphocytes count (p=0.002), uric acid (p=0.032) and GFR (p=0.000) in the patients classifi ed based on MACE. MACE was signifi cantly associated with hypertension (PR=1.285;95%CI=1.102-1.498;p=0.006). Chisquare analysis showed that stroke (PR=2.386;95%CI=1.271-4.480;p=0.007), heart failure (PR=2.533;95%CI=1.574-4.078;p=0.000), and malignant arrhythmia (PR=1.820;95%CI=1.229-2.694;p=0.004) were signifi cantly associated with hypertension. Association of hypertension and kidney disease were signifi cantly associated with stroke (PR= 2.386;p=0.007), malignant arrhythmia (PR=1.820;95%CI=1.229-2.694;p=0.004) and heart failure (PR=2.533;95%CI=1.574-4.078;p=0.000). Association of hypertension and COVID-19 were also signifi cantly associated with malignant arrhythmia (PR= 2.253;p=0.011). Conclusion:There were signifi cant association between hypertension with MACE in the patients. Intervention on these factors can prevent further mortality.
Introduction. Many research have looked into the potential of various biomarkers as predictors of intrahospital mortality in patients with STEMI. Patients with a history of heart failure, patients with STEMI with cardiogenic shock, and patients with heart failure all had a similar association between pro-BNP NT and intra-hospital mortality. In STEMI patients, troponin is another biomarker that can be utilized to predict intrahospital mortality with NT pro BNP. Objective. This study looked into the correlation between NT pro BNP and troponin I and intrahospital mortality in STEMI patients who had had PCI at RSUD dr. Saiful Anwar Malang. Material and Methods. A retrospective cohort research with an observational analysis design, targeted 391 STEMI patients who underwent PCI at RSUD dr. Saiful Anwar Malang between January 2018 and August 2022. Result. With AUC NT pro BNP 0.840 (95% confidence interval [CI]: 0.789 – 0.892) and troponin I AUC 0.818 (95% CI: 0.753 – 0.882), the ROC curve demonstrated a high degree of discriminating. The NT pro BNP 4390 cutoff value was also derived from the ROC analysis with a sensitivity of 0.882 and a specificity of 0.882. The threshold for troponin I was 7.9, with a sensitivity of 0.725 and a specificity of 0.80. From the examination of the connection, it was determined that there was a high link between NT pro BNP and intrahospital mortality in AMI EST patients who had had PCI, with a R value of 0.70; OR 10,484 (95% confidence interval [CI]: 7,731–19,366). With a R value of 0.4, there was a moderate connection between troponin I and intrahospital mortality in STEMI patients who had had PCI; the odds ratio was 6,167 (95% confidence interval: 2,286–16,637). Conclusion. There were a strong and moderate correlation between NT pro BNP and troponin I, respectively, with inhospital mortality in STEMI patient.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.